Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Successfully Completes Open-Label Clinical Trial for OTIPRIO® in Patients with History of Otitis Media Requiring Tympanostomy Tubes

SAN DIEGO, Sept. 15, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
September 13, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces OTIPRIO® Data Presentation and Symposium at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting

SAN DIEGO, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
September 01, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present at Baird Global Healthcare Conference

SAN DIEGO, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
August 04, 2016 16:09 ET | Source: Otonomy, Inc.

Otonomy Reports Second Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
August 01, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Successfully Completes One-Year, Multiple-Dose Clinical Safety Trial for OTO-104 in Ménière’s Disease Patients

SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
July 28, 2016 16:30 ET | Source: Otonomy, Inc.

Otonomy to Report Second Quarter 2016 Financial Results and Provide Corporate Update

SAN DIEGO, July 28, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
June 09, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Initiates Patient Enrollment in Single Phase 3 Clinical Trial of OTIPRIO™ in Patients with Acute Otitis Externa

SAN DIEGO, June 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
May 20, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces Assignment of C Code and Pass-Through Payment Status for OTIPRIO™

SAN DIEGO, May 20, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
May 16, 2016 07:30 ET | Source: Otonomy, Inc.

Otonomy Announces OTIPRIO™ Data Presentation and Symposium at Combined Otolaryngology Spring Meetings

SAN DIEGO, May 16, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
May 09, 2016 16:15 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2016 Financial Results and Provides Corporate Update

SAN DIEGO, May 09, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...